Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...

The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies ...

AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...

HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the ...

AstraZeneca Plc‘s win over shareholders who challenged its $3 billion sale of biotech firm Viela Bio Inc. was affirmed Wednesday by the Delaware Supreme Court.

AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.

The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn ...

AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma treatment Fasenra.

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as ...